WO2010027830A3 - Methods for modulation of connective tissue growth factor expression - Google Patents

Methods for modulation of connective tissue growth factor expression Download PDF

Info

Publication number
WO2010027830A3
WO2010027830A3 PCT/US2009/054974 US2009054974W WO2010027830A3 WO 2010027830 A3 WO2010027830 A3 WO 2010027830A3 US 2009054974 W US2009054974 W US 2009054974W WO 2010027830 A3 WO2010027830 A3 WO 2010027830A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
compound
connective tissue
tissue growth
subject
Prior art date
Application number
PCT/US2009/054974
Other languages
French (fr)
Other versions
WO2010027830A2 (en
Inventor
Nicholas M. Dean
J. Gordon Foulkes
Niall O'donnell
Gregory Hardee
Original Assignee
Excaliard Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excaliard Pharmaceuticals, Inc. filed Critical Excaliard Pharmaceuticals, Inc.
Publication of WO2010027830A2 publication Critical patent/WO2010027830A2/en
Publication of WO2010027830A3 publication Critical patent/WO2010027830A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides an improved method for reducing scarring resulting from wound healing in a subject in need thereof and treating fibrotic diseases and neoplastic diseases, which comprises administering to the subject a modified antisense compound which inhibits expression of connective tissue growth factor wherein the modified compound is administered to a delivery system which enhances uptake of the compound into and/or increases residence time of the compound in the subject's skin.
PCT/US2009/054974 2008-08-25 2009-08-26 Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases WO2010027830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19018408P 2008-08-25 2008-08-25
US61/190,184 2008-08-25

Publications (2)

Publication Number Publication Date
WO2010027830A2 WO2010027830A2 (en) 2010-03-11
WO2010027830A3 true WO2010027830A3 (en) 2010-04-29

Family

ID=41797787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054974 WO2010027830A2 (en) 2008-08-25 2009-08-26 Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases

Country Status (1)

Country Link
WO (1) WO2010027830A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102016036B (en) 2008-02-11 2015-04-08 阿克赛医药公司 Modified RNAi polynucleotides and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
US8252762B2 (en) 2008-08-25 2012-08-28 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3336188B1 (en) 2008-09-22 2020-05-06 Phio Pharmaceuticals Corp. Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
RU2615143C2 (en) 2010-03-24 2017-04-04 Адвирна Self-delivered rnai compounds of reduced size
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rna interference in dermal and fibrotic indications
KR101249041B1 (en) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 Pharmaceutical composition using connective-tissue growth factor
JP6177692B2 (en) * 2011-02-02 2017-08-09 エクスカリアード・ファーマシューティカルズ，インク Treatment of keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
US8802839B2 (en) 2011-07-15 2014-08-12 Fibrogen, Inc. Connective tissue growth factor antisense oligonucleotides
JP6772062B2 (en) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Cancer immunotherapy
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN107073294A (en) 2014-09-05 2017-08-18 阿克赛医药公司 Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder
AU2016279897A1 (en) 2015-06-15 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180300A1 (en) * 1998-12-14 2003-09-25 Grotendorst Gary R. Connective tissue growth factor fragments and methods and uses thereof
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180300A1 (en) * 1998-12-14 2003-09-25 Grotendorst Gary R. Connective tissue growth factor fragments and methods and uses thereof
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANTOS ET AL.: "Intraocular Delivery of Oligonucleotides.", CURR PHARM BIOTECH FEBRUARY, vol. 6, no. 1, 2005, pages 7 - 15 *

Also Published As

Publication number Publication date
WO2010027830A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2010027830A3 (en) Methods for modulation of connective tissue growth factor expression
WO2009129437A3 (en) Methods and compositions for treating post-operative pain comprising clonidine
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2007100675A3 (en) Collagenase for treating cellulite
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
MX343397B (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof.
WO2009134967A3 (en) Use of nucleic acids with reduced pressure therapy for treating wounds
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2012078561A3 (en) A drape having microstrain inducing projections for treating a wound site
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EA201070740A1 (en) METHOD OF TREATING BONE FRACTURE WITH ANTIBODIES AGAINST SKLEROSTIN
WO2005102307A3 (en) Beneficial effects of increasing local blood flow
MXPA02000721A (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation.
WO2009016451A9 (en) Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound
NZ603028A (en) Tfpi inhibitors and methods of use
WO2005072057A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO2012018545A3 (en) Systems and methods for treatment of sleep apnea
HK1082203A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
WO2007070637A3 (en) Method of treating open wounds using hypochlorous acid
WO2006078870A3 (en) Methods for treating adhesive capsulitis
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09812034

Country of ref document: EP

Kind code of ref document: A2